---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-21-001258"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2021-10-27T23:59:59+00:00"
generated_at: "2026-06-28T17:42:55.634539+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Teva Q3 revenues $3.9B (-2% YoY), non-GAAP EPS $0.59 vs $0.58; reaffirms FY guidance

## Summary
- GAAP diluted EPS $0.26 on net income $292M (vs loss $4.349B in Q3 2020).
- Non-GAAP diluted EPS $0.59 on net income $651M (up from $0.58).
- Free cash flow $795M; operating cash flow $529M.
- FY 2021 outlook: revenue $16.0-16.4B, adj. EBITDA $4.8-5.1B, EPS $2.50-2.70, FCF $2.0-2.3B.
- Announced collaboration with MODAG GmbH for movement disorder products; issued Sustainability-Linked Bond.

## SEC filing metadata
- accession: 0001157523-21-001258
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2021-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000115752321001258/0001157523-21-001258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000115752321001258/a52515881.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-21-001258
- JSON: https://secwatch.observer/filing/0001157523-21-001258.json
- Plain text: https://secwatch.observer/filing/0001157523-21-001258.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.